MX2016006725A - Moduladores de receptores de glucocorticoides de azadecalina octahidro fusionada. - Google Patents

Moduladores de receptores de glucocorticoides de azadecalina octahidro fusionada.

Info

Publication number
MX2016006725A
MX2016006725A MX2016006725A MX2016006725A MX2016006725A MX 2016006725 A MX2016006725 A MX 2016006725A MX 2016006725 A MX2016006725 A MX 2016006725A MX 2016006725 A MX2016006725 A MX 2016006725A MX 2016006725 A MX2016006725 A MX 2016006725A
Authority
MX
Mexico
Prior art keywords
glucocorticoid receptor
fused azadecalin
receptor modulators
octahydro fused
azadecalin glucocorticoid
Prior art date
Application number
MX2016006725A
Other languages
English (en)
Other versions
MX368167B (es
Inventor
Hunt Hazel
Walters Iain
Gourdet Benoit
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Publication of MX2016006725A publication Critical patent/MX2016006725A/es
Publication of MX368167B publication Critical patent/MX368167B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención provee compuestos de azadecalina octahidrofusionada y métodos para usar los compuestos como moduladores de receptores de glucocorticoides.
MX2016006725A 2013-11-25 2014-11-21 Moduladores de receptores de glucocorticoides de azadecalina octahidro fusionada. MX368167B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361908333P 2013-11-25 2013-11-25
US201461985035P 2014-04-28 2014-04-28
PCT/US2014/066759 WO2015077530A1 (en) 2013-11-25 2014-11-21 Octahydro fused azadecalin glucocorticoid receptor modulators

Publications (2)

Publication Number Publication Date
MX2016006725A true MX2016006725A (es) 2016-09-09
MX368167B MX368167B (es) 2019-09-23

Family

ID=53180165

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006725A MX368167B (es) 2013-11-25 2014-11-21 Moduladores de receptores de glucocorticoides de azadecalina octahidro fusionada.

Country Status (20)

Country Link
US (7) US10047082B2 (es)
EP (4) EP3560493B1 (es)
JP (5) JP6516743B2 (es)
KR (1) KR102352737B1 (es)
CN (2) CN109761976B (es)
AU (1) AU2014352915B2 (es)
BR (1) BR112016011826B1 (es)
CA (1) CA2931302C (es)
DK (2) DK3848027T3 (es)
ES (3) ES2743620T3 (es)
FI (1) FI3848027T3 (es)
IL (1) IL245848B (es)
MX (1) MX368167B (es)
MY (1) MY180141A (es)
PH (1) PH12016500968B1 (es)
PL (3) PL3848027T3 (es)
PT (2) PT3848027T (es)
RU (1) RU2674983C1 (es)
WO (1) WO2015077530A1 (es)
ZA (1) ZA201604026B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
ES2743620T3 (es) 2013-11-25 2020-02-20 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro
ES2906778T3 (es) 2015-03-30 2022-04-20 Corcept Therapeutics Inc Uso de antagonistas del receptor de glucocorticoides en combinación con glucocorticoides para tratar la insuficiencia suprarrenal
US10980797B2 (en) 2016-03-01 2021-04-20 Corcept Therapeutics Incorporated Use of glucocorticoid receptor modulators to potentiate checkpoint inhibitors
CN106478464B (zh) * 2016-08-30 2018-06-05 黄河三角洲京博化工研究院有限公司 一种2-氟-6-三氟甲基苯磺酰氯的制备方法
US9943505B2 (en) 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer
CN110475558A (zh) 2017-03-09 2019-11-19 科赛普特治疗学股份有限公司 糖皮质激素受体调节剂在儿茶酚胺分泌型肿瘤治疗中的应用
UA127409C2 (uk) * 2017-03-31 2023-08-16 Корцепт Терап'Ютікс, Інк. Модулятори глюкокортикоїдного рецептора для лікування раку шийки матки
WO2018209142A2 (en) * 2017-05-10 2018-11-15 Corcept Therapeutics, Inc. Octahydro azadecalin formulations
AU2018289307B2 (en) 2017-06-20 2024-02-01 Corcept Therapeutics, Inc. Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
IL278125B (en) * 2018-04-23 2022-09-01 Corcept Therapeutics Inc Methods for the preparation of regioselective n-alkyl triazoles
AR117951A1 (es) * 2018-07-20 2021-09-08 Gruenenthal Gmbh Derivados de triazolquinoxalina adicionalmente sustituidos
IL263184A (en) 2018-11-21 2020-05-31 Yarden Yosef Method of treating cancer and compositions for same
CN117281790A (zh) 2018-12-19 2023-12-26 科塞普特治疗公司 含有瑞拉可兰、杂芳基-酮稠合的氮杂十氢化萘化合物的药物制剂
US11234971B2 (en) 2018-12-19 2022-02-01 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
US11389432B2 (en) 2018-12-19 2022-07-19 Corcept Therapeutics Incorporated Methods of treating cancer comprising administration of a glucocorticoid receptor modulator and a cancer chemotherapy agent
MX2021010135A (es) * 2019-02-22 2021-09-23 Corcept Therapeutics Inc Usos terapeuticos de relacorilante, un modulador del receptor de glucocorticoides de azadecalina fusionada con heteroaril-cetona.
MX2022004487A (es) 2019-10-16 2022-05-06 Corcept Therapeutics Inc Metodo para normalizar el indice de neutrofilos a linfocitos en pacientes con cancer con un antagonista del receptor de glucocorticoide selectivo.
US11903945B2 (en) 2019-12-11 2024-02-20 Corcept Therapeutics Incorporated Methods of treating antipsychotic-induced weight gain with miricorilant
WO2021127376A1 (en) 2019-12-21 2021-06-24 Corcept Therapeutics Incorporated Treatment of, and differential diagnosis between, acth-dependent cushing's syndrome and acth-independent cushing's syndrome
CN116113627A (zh) 2020-06-22 2023-05-12 科赛普特治疗公司 季吲哚糖皮质激素受体拮抗剂
WO2022134033A1 (en) * 2020-12-25 2022-06-30 Corcept Therapeutics Incorporated Methods of preparing heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
TW202246260A (zh) * 2021-02-03 2022-12-01 大陸商江蘇恆瑞醫藥股份有限公司 稠合的氮雜三環類衍生物、其製備方法及其在醫藥上的應用

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS322220B1 (es) 1954-11-30 1957-04-11
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
IL72729A (en) 1983-09-26 1988-02-29 Lilly Co Eli Trans(+_)octahydropyrazole-ring alkylated pyrazoloquinolines,their preparation and pharmaceutical compositions containing them
GB8828669D0 (en) * 1988-12-08 1989-01-11 Lilly Industries Ltd Organic compounds
JP3160941B2 (ja) 1991-06-17 2001-04-25 東レ株式会社 カルバゾール誘導体および免疫抑制剤
FR2697252B1 (fr) 1992-10-28 1994-12-09 Fournier Ind & Sante Dérivés de 1,2,3,5,6,7,8,8a-octahydro-5,5,8a-triméthyl-(8abeta)-6-isoquinolineamine, leur procédé de préparation et leur utilisation en thérapeutique.
JPH09505030A (ja) 1993-08-06 1997-05-20 スミスクライン・ビーチャム・ソシエタ・ペル・アチオニ ヒドロイソキノリン誘導体
AU756983B2 (en) 1998-03-10 2003-01-30 Research Triangle Institute Novel opiate compounds, methods of making and methods of use
GB9911053D0 (en) 1999-05-12 1999-07-14 Pharmacia & Upjohn Spa 4,5,6,7-tetrahydroindazole derivatives process for their preparation and their use as antitumour agents
US7238778B2 (en) 2001-07-17 2007-07-03 Smithkline Beecham Corporation Crystallized glucocorticoid receptor ligand binding domain polypeptide and screening methods employing same
MXPA04000692A (es) * 2001-07-23 2004-04-21 Corcept Therapeutics Inc MeTODOS PARA EVITAR GANANCIA DE PESO INDUCIDA ANTISICOTICA.
US6679935B2 (en) * 2001-08-14 2004-01-20 Apex Advanced Technologies, Llc Lubricant system for use in powdered metals
WO2003061651A1 (en) 2002-01-22 2003-07-31 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
JP2007504226A (ja) 2003-09-03 2007-03-01 ワイス 非晶質状のラパマイシンの３−ヒドロキシ−２−（ヒドロキシメチル）−２−メチルプロピオン酸との４２−エステル、およびそれを含むその医薬組成物
DE602005009530D1 (de) 2004-01-09 2008-10-16 Corcept Therapeutics Inc Azadecalinmodulatoren des glucocorticoidrezeptors
CN101027301B (zh) * 2004-03-09 2011-06-29 科塞普特治疗公司 稠环氮杂十氢化萘糖皮质激素受体调节剂
DK1928840T3 (da) * 2005-04-05 2011-09-12 Hoffmann La Roche 1H-pyrazol-4-carboxamider, deres fremstilling og deres anvendelse som 11-beta-hydroxysteroid-dehydrogenaseinhibitorer
US7790745B2 (en) 2005-10-21 2010-09-07 Bristol-Myers Squibb Company Tetrahydroisoquinoline LXR Modulators
EP2209780B1 (en) * 2007-11-01 2014-01-01 Bristol-Myers Squibb Company Nonsteroidal compounds useful as modulators of glucocorticoid receptor ap-1 and/or nf- kappa b activity and use thereof
EP2247597A1 (en) * 2008-02-07 2010-11-10 Bristol-Myers Squibb Company Fused heteroaryl modulators of glucocorticoid receptor, ap-1, and/or nf-kb activity and use thereof
ES2531040T3 (es) 2009-05-12 2015-03-10 Corcept Therapeutics Inc Formas sólidas y procedimiento de preparación
US8710035B2 (en) * 2010-03-24 2014-04-29 The University Of Chicago Methods and compositions related to glucocorticoid receptor antagonists and breast cancer
CN103080108A (zh) * 2010-08-27 2013-05-01 科赛普特治疗公司 吡啶基-胺稠合的氮杂萘烷调节剂
AU2012204232A1 (en) 2011-01-07 2013-06-27 Corcept Therapeutics, Inc. Combination steroid and glucocorticoid receptor antagonist therapy
WO2013130420A1 (en) 2012-02-27 2013-09-06 Corcept Therapeutics, Inc. Phenyl heterocycloalkyl glucocorticoid receptor modulators
ES2753816T3 (es) 2012-05-25 2020-04-14 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides de azadecalina condensada con heteroaril-cetona
US8859774B2 (en) 2012-05-25 2014-10-14 Corcept Therapeutics, Inc. Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
ES2743620T3 (es) 2013-11-25 2020-02-20 Corcept Therapeutics Inc Moduladores del receptor de glucocorticoides de azadecalina condensada con octahidro
US9943505B2 (en) * 2016-09-09 2018-04-17 Corcept Therapeutics, Inc. Glucocorticoid receptor modulators to treat pancreatic cancer

Also Published As

Publication number Publication date
WO2015077530A1 (en) 2015-05-28
IL245848B (en) 2020-08-31
JP6516743B2 (ja) 2019-05-22
KR20160089506A (ko) 2016-07-27
EP3848027B1 (en) 2023-04-05
EP3560493B1 (en) 2021-03-31
EP3848027A1 (en) 2021-07-14
CN106029066A (zh) 2016-10-12
RU2016123449A (ru) 2017-12-28
US20150148341A1 (en) 2015-05-28
CN109761976A (zh) 2019-05-17
MY180141A (en) 2020-11-23
NZ720969A (en) 2021-05-28
US20200361935A1 (en) 2020-11-19
PL3560493T3 (pl) 2021-10-04
JP2021073315A (ja) 2021-05-13
JP2023011052A (ja) 2023-01-20
ES2869172T3 (es) 2021-10-25
US11560379B2 (en) 2023-01-24
PL3074011T3 (pl) 2020-01-31
RU2674983C1 (ru) 2018-12-14
CA2931302C (en) 2021-12-07
BR112016011826B1 (pt) 2022-09-27
IL245848A0 (en) 2016-07-31
ES2743620T3 (es) 2020-02-20
AU2014352915A1 (en) 2016-06-30
US20190241563A1 (en) 2019-08-08
DK3848027T3 (da) 2023-05-01
US20190135805A1 (en) 2019-05-09
DK3074011T3 (da) 2019-09-30
JP2019094355A (ja) 2019-06-20
JP2016537394A (ja) 2016-12-01
PT3074011T (pt) 2019-09-17
EP3560493A1 (en) 2019-10-30
US10323034B2 (en) 2019-06-18
PL3848027T3 (pl) 2023-07-24
EP3074011A1 (en) 2016-10-05
ES2943542T3 (es) 2023-06-14
KR102352737B1 (ko) 2022-01-17
EP3074011B1 (en) 2019-07-24
BR112016011826A2 (es) 2017-08-08
JP2018012734A (ja) 2018-01-25
EP3074011A4 (en) 2017-05-31
AU2014352915B2 (en) 2018-03-15
CN109761976B (zh) 2021-11-23
US20210139478A1 (en) 2021-05-13
MX368167B (es) 2019-09-23
CN106029066B (zh) 2019-03-15
PH12016500968A1 (en) 2016-07-18
CA2931302A1 (en) 2015-05-28
US20230167111A1 (en) 2023-06-01
PH12016500968B1 (en) 2016-07-18
PT3848027T (pt) 2023-05-11
EP4219494A1 (en) 2023-08-02
US10787449B2 (en) 2020-09-29
US20190048004A1 (en) 2019-02-14
FI3848027T3 (fi) 2023-05-04
ZA201604026B (en) 2019-03-27
US10047082B2 (en) 2018-08-14
US11370789B2 (en) 2022-06-28

Similar Documents

Publication Publication Date Title
PH12016500968A1 (en) Octahydro fused azadecalin glucocorticoid receptor modulators
PH12015502621A1 (en) Estrogen receptor modulator and uses thereof
MX2015011132A (es) Moduladores policiclicos del receptor de estrogenos y sus usos.
PH12014502095A1 (en) Estrogen receptor modulators and uses thereof
MX2015016171A (es) Moduladores del receptor de estrogeno de azetidina y usos de los mismos.
MX2019005192A (es) Compuestos de quinolina selectivamente sustituida.
ZA201901135B (en) Glucocorticoid receptor modulators to treat pancreatic cancer
MY172739A (en) Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
NZ737399A (en) Ccr2 modulators
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
GB201804682D0 (en) Test system for anti-dc component and even-order harmonic of current
NZ630908A (en) Heterocyclic compounds and methods of their use
IN2014KN02993A (es)
EP3087987A4 (en) Pharmaceutical composition containing palonosetron
PH12017500348A1 (en) Tetrahydroquinoline derivatives as bromodomain inhibitors
TN2014000136A1 (en) Selective androgen receptor modulators
CL2013000069A1 (es) Compuestos derivados de heterociclos fusionados, moduladores s1p; composicion farmaceutica; y uso en enfermedades neurodegenerativas.
MX2015008588A (es) Composiciones y metodos para la transfeccion de polinucleótidos.
GEP201706764B (en) Quinazolin-thf-amines as pde1 inhibitors
EP3375887A4 (en) METHOD FOR DETERMINING THE RESISTANCE TO ANTICREBREPHERIC AND COMPOSITION USED THEREFOR
MX371343B (es) Moduladores del receptor x hepatico (lxr).
MX2016002930A (es) Moduladores del receptor x hepatico (lxr).
EP3143005A4 (en) Chemokine cxcr4 and ccr5 receptor modulators and used related thereto
MX368870B (es) Uso de un antagonista de receptores de opioides con actividad kappa y vortioxetina para el tratamiento de trastorno depresivo con características melancólicas.

Legal Events

Date Code Title Description
FG Grant or registration